Ambrx's CEO & CSO discuss the ADC space and recent #ESMO23 data
Dan O'Connor and Shawn Zhang describe Ambrx's HER2 and PSMA targeting antibody-drug conjugate programs, recent prostate cancer data at ESMO, and how they think about the competitive landscape.